跳转至内容
Merck
CN
所有图片(1)

主要文件

1011029

USP

Acitretin Related Compound B

United States Pharmacopeia (USP) Reference Standard

别名:

Ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate, Etretinate

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C23H30O3
CAS号:
分子量:
354.48
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

acitretin

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

O(C)c1c(c(c(c(c1)C)\C=C\C(=C\C=C\C(=C\C(=O)OCC)\C)\C)C)C

InChI

1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+

InChI key

HQMNCQVAMBCHCO-DJRRULDNSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Acitretin Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Acitretin

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

警示用语:

Danger

危险分类

Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1A - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Primary cutaneous CD30+ lymphoproliferative disorder successfully treated by etretinate.
Satoshi Nakamura et al.
European journal of dermatology : EJD, 22(5), 709-710 (2012-08-30)
Emiko Akasaka et al.
The Journal of dermatology, 40(4), 238-243 (2013-01-22)
Various therapies have been tried for psoriasis. In Japan, biologics began to be used for psoriasis treatment in January 2010. Their clinical efficacy is well known, but biologics cannot be used in all psoriasis patients for reasons such as side-effects
R A Abbott et al.
Clinical and experimental dermatology, 34(3), 378-379 (2009-03-25)
Pityriasis rubra pilaris (PRP) is an uncommon, idiopathic, papulosquamous eruption. We report a longitudinal study of a patient with PRP type 1 who was treated with retinoid therapy for 9 years and whose symptoms resolved spontaneously after 20 years. There
Stanislava Stosić-Grujicić et al.
Molecular immunology, 47(1), 79-86 (2009-02-13)
Retinoids have a variety of biological activities, including immunomodulatory action in a number of inflammatory and autoimmune conditions. Considering the pathogenesis of type 1 diabetes mellitus (T1D), in this study we examined the potential role for retinoids, etretinate and all-trans-retinoic
H-D Park et al.
International journal of clinical pharmacology and therapeutics, 47(7), 476-482 (2009-07-31)
Acitretin is used for the treatment of psoriasis. The purpose of this study was to validate an HPLC method for the determination of acitretin and etretinate and to investigate the pharmacokinetic characteristics of acitretin in healthy Korean subjects. Plasma samples

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门